• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Schizophrenia research >Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.
【24h】

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

机译：首发精神分裂症患者脑脊液中的Anandamide水平：大麻的使用影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Previous studies have shown that cerebrospinal fluid (CSF) from schizophrenic patients contains significantly higher levels of the endogenous cannabinoid anandamide than does CSF from healthy volunteers. Moreover, CSF anandamide levels correlated inversely with psychotic symptoms, suggesting that anandamide release in the central nervous system (CNS) may serve as an adaptive mechanism countering neurotransmitter abnormalities in acute psychoses. In the present study we examined whether cannabis use may alter such a mechanism. METHODS: We used liquid chromatography/mass spectrometry (LC/MS) to measure anandamide levels in serum and CSF from first-episode, antipsychotic-naive schizophrenics (n=47) and healthy volunteers (n=81). Based on reported patterns of cannabis use and urine delta9-tetrahydrocannabinol (delta9-THC) tests, each subject group was further divided into two subgroups: 'low-frequency' and 'high-frequency' cannabis users (lifetime use < or = 5 times and > 20 times, respectively). Serum delta9-THC was investigated to determine acute use and three patients were excluded from the analysis due to detectable delta9-THC levels in serum. RESULTS: Schizophrenic low-frequency cannabis users (n=25) exhibited > 10-fold higher CSF anandamide levels than did schizophrenic high-frequency users (n=19, p=0.008), healthy low-frequency (n=55, p<0.001) or high-frequency users (n=26, p<0.001). In contrast, no significant differences in serum anandamide levels were found among the four subgroups. CSF anandamide levels and disease symptoms were negatively correlated in both user groups. CONCLUSIONS: The results indicate that frequent cannabis exposure may down-regulate anandamide signaling in the CNS of schizophrenic patients, but not of healthy individuals. Thus, our findings suggest that alterations in endocannabinoid signaling might be an important component of the mechanism through which cannabis impacts mental health.
机译：背景：先前的研究表明，精神分裂症患者的脑脊液（CSF）内源性大麻素an南酰胺的含量明显高于健康志愿者的脑脊液。此外，脑脊液中的anandamide水平与精神病症状呈负相关，表明中枢神经系统（CNS）中的anandamide释放可能是抵抗急性精神病中神经递质异常的适应性机制。在本研究中，我们研究了大麻的使用是否会改变这种机制。方法：我们使用液相色谱/质谱法（LC / MS）测定了首发，初次使用抗精神病精神分裂症患者（n = 47）和健康志愿者（n = 81）的血清和脑脊液中的anandamide水平。根据报告的大麻使用方式和尿液中delta9-tetrahydrocannabinol（delta9-THC）测试，每个受试者组进一步分为两个亚组：“低频率”和“高频率”大麻使用者（终生使用<或= 5次和>分别大于20次）。对血清delta9-THC进行了研究以确定急性使用情况，由于血清中可检测到的delta9-THC水平，三名患者被排除在分析之外。结果：精神分裂症的低频率大麻使用者（n = 25）的CSF大麻素水平比精神分裂症的高频率使用者（n = 19，p = 0.008），健康的低频人群（n = 55，p < 0.001）或高频用户（n = 26，p <0.001）。相比之下，在四个亚组之间未发现血清中的山and酰胺水平有显着差异。在两个使用者组中，CSF anandamide水平和疾病症状呈负相关。结论：结果表明，频繁的大麻暴露可能会下调精神分裂症患者中枢神经系统中的anandamide信号，但对健康个体而言却不然。因此，我们的发现表明，内源性大麻素信号传导的改变可能是大麻影响心理健康的机制的重要组成部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号